SEC Company Response from PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Feb 6, 2020
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Feb. 6, 2020 · CIK: 0001472091 · Accession: 0001140361-20-002491
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235549
Letter
Re:
February 6, 2020
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
PDS Biotechnology Corporation
Registration Statement on Form S-1
File No. 333-235549
Ladies and Gentlemen:
PDS Biotechnology Corporation hereby withdraws its prior acceleration request dated February 5, 2020, for the above-referenced Registration Statement on Form S-1.
Please direct any questions or comments regarding this correspondence to Fahd Riaz at (215) 656-3316 or Emilio Ragosa at (973) 307-3004, each of DLA Piper LLP (US).
Thank you for your assistance.
Sincerely,
PDS BIOTECHNOLOGY CORPORATION
Show Raw Text
CORRESP
1
filename1.htm
February 6, 2020
VIA EDGAR
Securities and Exchange Commission
100 F. Street, N.E.
Washington, D.C. 20549
Re:
PDS Biotechnology Corporation
Registration Statement on Form S-1
File No. 333-235549
Ladies and Gentlemen:
PDS Biotechnology Corporation hereby withdraws its prior acceleration request dated February 5, 2020, for the above-referenced Registration Statement on Form
S-1.
Please direct any questions or comments regarding this correspondence to Fahd Riaz at (215) 656-3316 or Emilio Ragosa at (973) 307-3004, each of DLA Piper LLP
(US).
Thank you for your assistance.
Sincerely,
PDS BIOTECHNOLOGY CORPORATION
By: /s/ Frank Bedu-Addo, Ph.D.
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer